Ajanta Pharma Q3 FY26 Revenue Up 20% to ₹1,375 Cr, PAT Up 18% to ₹274 Cr
Ajanta Pharma reported Q3 FY26 revenue of ₹1,375 crore, a 20% increase year-on-year. PAT rose 18% to ₹274 crore. For 9M FY26, revenue was ₹4,031 crore (up 16%) and PAT was ₹789 crore (up 14%). Branded Generics in India grew 19%, and US Generics surged 52% in Q3 FY26. An earnings conference call is scheduled for January 30, 2026.
The announcement contains strong financial results with significant growth percentages in revenue and profit, which are key performance indicators for investors. The positive performance across major business segments suggests a substantial positive impact on the company's financial standing and investor confidence.
The company reported strong year-on-year growth in both revenue and profit for the quarter and nine months ended December 31, 2025, with significant increases in key segments like Branded Generics and US Generics. The results exceeded expectations and indicate positive business momentum.
Ajanta Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on January 30, 2026. The company reported a significant increase in revenue from operations by 20% to ₹1,375 crore for Q3 FY26, compared to ₹1,146 crore in Q3 FY25. Profit After Tax (PAT) also saw an 18% rise, reaching ₹274 crore from ₹233 crore in the same period.
For the nine-month period ended December 31, 2025 (9M FY26), revenue from operations grew by 16% to ₹4,031 crore from ₹3,478 crore in 9M FY25. PAT for 9M FY26 increased by 14% to ₹789 crore from ₹695 crore in 9M FY25. The company highlighted strong performance in its Branded Generics segment, particularly in India, where revenue grew by 19% to ₹409 crore in Q3 FY26. The US Generic business also showed robust growth, with revenue up by 52% to ₹399 crore in Q3 FY26.
The company's R&D expenses for Q3 FY26 were ₹63 crore, representing 5% of revenue, and for 9M FY26 were ₹182 crore, also 5% of revenue. Ajanta Pharma also announced an Earnings Conference Call scheduled for January 30, 2026, at 16:30 hrs IST to discuss its financial performance.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.